Personenfreizügigkeit und Wohnungsmarkt

Die Lage auf dem Schweizer Wohnungsmarkt hat sich im Jahr 2010 leicht entspannt. Dazu beigetragen haben eine starke Neubautätigkeit und das im Vorjahr abgeflachte Bevölkerungswachstum. Die knappsten Märkte befinden sich weiterhin in der Grossregion Zürich und Teilen der Westschweiz. Dies zeigt die im Juli 2011 aktualisierte Untersuchung der Auswirkungen der Personenfreizügigkeit auf den Wohnungsmarkt, die im Auftrag des Bundesamtes für Wohnungswesen in Zusammenarbeit mit der Meta-Sys AG, Zürich, entstanden ist

Personenfreizügigkeit und Wohnungsmarkt : Schweiz : Entwicklung 2012

Seit der Mitte des vergangenen Jahrzehnts beeinflusst die Einführung der Personenfreizügigkeit die Einwanderungsrate in die Schweiz. Zu beobachten sind strukturelle Änderungen der Zuwanderung, einerseits was die Herkunft, andererseits was die Qualifikation der Ausländer betrifft. Immer mehr Zuwanderer stammen aus Ländern der europäischen Union und ihr Qualifikationsniveau ist höher als früher. Dies wirkt sich auch auf den Markt für Wohnimmobilien aus

Personenfreizügigkeit und Wohnungsmarkt : Entwicklung 2015 : Schweiz

Seit der Mitte des vergangenen Jahrzehnts beeinflusst die Einführung der Personenfreizügigkeit die Einwan­derungsrate in die Schweiz. Im Vergleich zu früher bewirkte dies zuerst strukturelle Änderungen, einerseits was die Herkunft, andererseits was die Qualifikation der Ausländer betraf. Mittlerweile ist dieser Effekt nicht mehr so ausgeprägt, geblieben sind aber hohe Zuwanderungsraten. Dies wirkt sich auf den Markt für Wohnimmobilien aus. Das Ziel dieses Berichts ist es, die Entwicklung der ausländischen Haushalte zu verfolgen und ihren Einfluss auf den Wohnungsmarkt darzustellen. Dabei wird der aktuelle Zustand des Marktes den Wachstumsraten der Haushalte und ihrer Einkommensstruktur gegenübergestellt. Dazu wird der Wohnungs­markt in zwei Teile unterteilt: Miete und Eigentum. Diese beiden Teile sind weiter unterteilt in drei Preisseg­mente: tiefes, mittleres und hohes Preissegment

Personenfreizügigkeit und Wohnungsmarkt : Entwicklung 2014 : Schweiz

Seit Mitte des vergangenen Jahrzehnts beeinflusst die Einführung der Personenfreizügigkeit die Einwanderungsrate in die Schweiz. Zu beobachten sind strukturelle Änderungen der Zuwanderung, einerseits was die Herkunft, andererseits was die Qualifikation der Ausländer betrifft. Immer mehr Zuwanderer stammen aus Ländern der europäischen Union und ihr Qualifikationsniveau ist höher als früher. Dies wirkt sich auch auf den Markt für Wohnimmobilien aus.

Using an Electronic Mindfulness-based Intervention (eMBI) to improve maternal mental health during pregnancy: Results from a randomized controlled trial

Prevalence rates of peripartum depression and anxiety are high and correlate with adverse maternal and neonatal outcomes. Mindfulness-based interventions (MBI) have been shown to reduce mental distress during pregnancy. A multicenter, randomized controlled study was conducted after screening for depressive symptoms. The intervention group (IG) was given access to an 8-week supervised eMBI between weeks 29 and 36 of pregnancy and followed up to 5 months postpartum. Psychometric data were collected using the Edinburgh Postnatal Depression Scale (EPDS), the State-Trait Anxiety Inventory (STAI), the Pregnancy-Related Anxiety Questionnaire (PRAQ-R), the Freiburg Mindfulness Inventory (FMI-14) as well as the Patient Health Questionnaire (PHQ). Out of 5299 pregnant women, 1153 scored >9 on the EPDS and N = 460 were included in the RCT. No significant interaction effects for depressive symptoms and anxiety were found. Pregnancy- and birth-related anxiety decreased significantly in the IG and 6 weeks after birth, the rate of women at risk for adverse mental outcome was significantly lower compared to the CG. Mindfulness scores improved significantly in the IG. The eMBI program did not show effective regarding general depressive or anxiety symptoms, however, positive results were demonstrated regarding pregnancy and birth-related anxiety and the prevention of postpartum depression

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer

Objective Precision oncology depends on translating molecular data into therapy recommendations. However, with the growing complexity of next-generation sequencing-based tests, clinical interpretation of somatic genomic mutations has evolved into a formidable task. Here, we compared the performance of three commercial clinical decision support tools, that is, NAVIFY Mutation Profiler (NAVIFY; Roche), QIAGEN Clinical Insight (QCI) Interpret (QIAGEN) and CureMatch Bionov (CureMatch). Methods In order to obtain the current status of the respective tumour genome, we analysed cell-free DNA from patients with metastatic breast, colorectal or non-small cell lung cancer. We evaluated somatic copy number alterations and in parallel applied a 77-gene panel (AVENIO ctDNA Expanded Panel). We then assessed the concordance of tier classification approaches between NAVIFY and QCI and compared the strategies to determine actionability among all three platforms. Finally, we quantified the alignment of treatment suggestions across all decision tools. Results Each platform varied in its mode of variant classification and strategy for identifying druggable targets and clinical trials, which resulted in major discrepancies. Even the frequency of concordant actionable events for tier I-A or tier I-B classifications was only 4.3%, 9.5% and 28.4% when comparing NAVIFY with QCI, NAVIFY with CureMatch and CureMatch with QCI, respectively, and the obtained treatment recommendations differed drastically. Conclusions Treatment decisions based on molecular markers appear at present to be arbitrary and dependent on the chosen strategy. As a consequence, tumours with identical molecular profiles would be differently treated, which challenges the promising concepts of genome-informed medicine

Pedestrian Crowd Management Experiments: A Data Guidance Paper

Understanding pedestrian dynamics and the interaction of pedestrians with their environment is crucial to the safe and comfortable design of pedestrian facilities. Experiments offer the opportunity to explore the influence of individual factors. In the context of the project CroMa (Crowd Management in transport infrastructures), experiments were conducted with about 1000 participants to test various physical and social psychological hypotheses focusing on people's behaviour at railway stations and crowd management measures. The following experiments were performed: i) Train Platform Experiment, ii) Crowd Management Experiment, iii) Single-File Experiment, iv) Personal Space Experiment, v) Boarding and Alighting Experiment, vi) Bottleneck Experiment and vii) Tiny Box Experiment. This paper describes the basic planning and implementation steps, outlines all experiments with parameters, geometries, applied sensor technologies and pre- and post-processing steps. All data can be found in the pedestrian dynamics data archive.Comment: 58 pages, 19 figures, under review Collective Dynamic

Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases

Abstract The SARS‐CoV‐2 infection cycle is a multistage process that relies on functional interactions between the host and the pathogen. Here, we repurposed antiviral drugs against both viral and host enzymes to pharmaceutically block methylation of the viral RNA 2'‐O‐ribose cap needed for viral immune escape. We find that the host cap 2'‐O‐ribose methyltransferase MTr1 can compensate for loss of viral NSP16 methyltransferase in facilitating virus replication. Concomitant inhibition of MTr1 and NSP16 efficiently suppresses SARS‐CoV‐2 replication. Using in silico target‐based drug screening, we identify a bispecific MTr1/NSP16 inhibitor with anti‐SARS‐CoV‐2 activity in vitro and in vivo but with unfavorable side effects. We further show antiviral activity of inhibitors that target independent stages of the host SAM cycle providing the methyltransferase co‐substrate. In particular, the adenosylhomocysteinase (AHCY) inhibitor DZNep is antiviral in in vitro, in ex vivo, and in a mouse infection model and synergizes with existing COVID‐19 treatments. Moreover, DZNep exhibits a strong immunomodulatory effect curbing infection‐induced hyperinflammation and reduces lung fibrosis markers ex vivo. Thus, multispecific and metabolic MTase inhibitors constitute yet unexplored treatment options against COVID‐19